<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1167" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1167/" /><meta name="ncbi_pagename" content="Best Vitelliform Macular Dystrophy - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Best Vitelliform Macular Dystrophy - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Best Vitelliform Macular Dystrophy" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2013/12/12" /><meta name="citation_author" content="Ian M MacDonald" /><meta name="citation_author" content="Thomas Lee" /><meta name="citation_pmid" content="20301346" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1167/" /><meta name="citation_keywords" content="Best Macular Dystrophy" /><meta name="citation_keywords" content="Vitelliform Macular Dystrophy Type 2" /><meta name="citation_keywords" content="Best Macular Dystrophy" /><meta name="citation_keywords" content="Vitelliform Macular Dystrophy Type 2" /><meta name="citation_keywords" content="Bestrophin-1" /><meta name="citation_keywords" content="BEST1" /><meta name="citation_keywords" content="Best Vitelliform Macular Dystrophy" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Best Vitelliform Macular Dystrophy" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Ian M MacDonald" /><meta name="DC.Contributor" content="Thomas Lee" /><meta name="DC.Date" content="2013/12/12" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1167/" /><meta name="description" content="Best vitelliform macular dystrophy is a slowly progressive macular dystrophy with onset generally in childhood and sometimes in later teenage years. Affected individuals initially have normal vision followed by decreased central visual acuity and metamorphopsia. Individuals retain normal peripheral vision and dark adaptation. Age of onset and severity of vision loss show inter- and intrafamilial variability." /><meta name="og:title" content="Best Vitelliform Macular Dystrophy" /><meta name="og:type" content="book" /><meta name="og:description" content="Best vitelliform macular dystrophy is a slowly progressive macular dystrophy with onset generally in childhood and sometimes in later teenage years. Affected individuals initially have normal vision followed by decreased central visual acuity and metamorphopsia. Individuals retain normal peripheral vision and dark adaptation. Age of onset and severity of vision loss show inter- and intrafamilial variability." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1167/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/bvd/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1167/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8946B2E03F91910000000007BB031F.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1167_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1167_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/bscl/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/bpan/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1167_"><span class="title" itemprop="name">Best Vitelliform Macular Dystrophy</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: Best Macular Dystrophy, Vitelliform Macular Dystrophy Type 2</div><p class="contrib-group"><span itemprop="author">Ian M MacDonald</span>, MDCM and <span itemprop="author">Thomas Lee</span>, MD, MSc.</p><a data-jig="ncbitoggler" href="#__NBK1167_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1167_ai__"><div class="contrib half_rhythm"><span itemprop="author">Ian M MacDonald</span>, MDCM<div class="affiliation small">Department of Ophthalmology<br />University of Alberta<br />Edmonton, Alberta, Canada<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ac.atreblau@lanodcam" class="oemail">ac.atreblau@lanodcam</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Thomas Lee</span>, MD, MSc<div class="affiliation small">Department of Ophthalmology<br />University of Ottawa<br />Ottawa, Ontario, Canada<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ac.no.hot@eelsamoht" class="oemail">ac.no.hot@eelsamoht</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">September 30, 2003</span>; Last Update: <span itemprop="dateModified">December 12, 2013</span>.</p><p><em>Estimated reading time: 20 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="bvd.Summary" itemprop="description"><h2 id="_bvd_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Best vitelliform macular dystrophy is a slowly progressive macular dystrophy with onset generally in childhood and sometimes in later teenage years. Affected individuals initially have normal vision followed by decreased central visual acuity and metamorphopsia. Individuals retain normal peripheral vision and dark adaptation. Age of onset and severity of vision loss show inter- and <a class="def" href="/books/n/gene/glossary/def-item/intrafamilial-variability/">intrafamilial variability</a>.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of Best vitelliform macular dystrophy is based on fundus appearance, electrooculogram (EOG), and family history. Affected individuals have a typical yellow yolk-like macular lesion on fundus examination. Lesions are usually bilateral, but can be unilateral. The EOG indirectly measures the standing potential of the eye. A normal light peak / dark trough ratio (Arden ratio) is greater than 1.8. In Best vitelliform macular dystrophy, the EOG is abnormal with a reduced light peak / dark trough ratio almost always less than 1.5, typically between 1.0 and 1.3. The Arden ratio stays constant with age for these individuals. <i>BEST1</i> (<i>VMD2</i>) is the only <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> in which pathogenic variants are known to cause Best vitelliform macular dystrophy.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Low vision aids as needed. Direct laser photocoagulation and anti-vascular endothelial growth factors (anti-VEGF) for choroidal neovascularization and hemorrhage.</p><p><i>Surveillance:</i> Annual ophthalmologic examination for persons of all ages.</p><p><i>Agents/circumstances to avoid:</i> Smoking.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>Best vitelliform macular dystrophy is most commonly inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner; however, <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> inheritance has been reported in three families. For autosomal dominant Best vitelliform macular dystrophy:</p><ul><li class="half_rhythm"><div>Most individuals diagnosed with Best vitelliform macular dystrophy have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent.</div></li><li class="half_rhythm"><div>The proportion of cases caused by <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variants is unknown.</div></li><li class="half_rhythm"><div>Each child of an individual with Best vitelliform macular dystrophy has a 50% chance of inheriting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>Prenatal testing is possible for families in which the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is known.</div></li></ul></div></div><div id="bvd.Diagnosis"><h2 id="_bvd_Diagnosis_">Diagnosis</h2><div id="bvd.Clinical_Diagnosis"><h3>Clinical Diagnosis</h3><p>The diagnosis of Best vitelliform macular dystrophy is based on fundus appearance, electrooculogram (EOG), and family history.</p><p><b>Fundus appearance.</b> Affected individuals may have a typical yellow yolk-like macular lesion on fundus examination. Lesions are usually bilateral, but can be unilateral. Multiple lesions and lesions outside the macula occur in at least one quarter of individuals. See <a class="figpopup" href="/books/NBK1167/figure/bvd.F1/?report=objectonly" target="object" rid-figpopup="figbvdF1" rid-ob="figobbvdF1">Figure 1</a>, <a class="figpopup" href="/books/NBK1167/figure/bvd.F2/?report=objectonly" target="object" rid-figpopup="figbvdF2" rid-ob="figobbvdF2">Figure 2</a>, <a class="figpopup" href="/books/NBK1167/figure/bvd.F3/?report=objectonly" target="object" rid-figpopup="figbvdF3" rid-ob="figobbvdF3">Figure 3</a>.</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figbvdF1" co-legend-rid="figlgndbvdF1"><a href="/books/NBK1167/figure/bvd.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="figbvdF1" rid-ob="figobbvdF1"><img class="small-thumb" src="/books/NBK1167/bin/bvd-Image001.gif" src-large="/books/NBK1167/bin/bvd-Image001.jpg" alt="Figure 1. " /></a><div class="icnblk_cntnt" id="figlgndbvdF1"><h4 id="bvd.F1"><a href="/books/NBK1167/figure/bvd.F1/?report=objectonly" target="object" rid-ob="figobbvdF1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">Vitelliform stage (Stage 2) </p></div></div><div class="iconblock whole_rhythm clearfix ten_col fig" id="figbvdF2" co-legend-rid="figlgndbvdF2"><a href="/books/NBK1167/figure/bvd.F2/?report=objectonly" target="object" title="Figure 2. " class="img_link icnblk_img figpopup" rid-figpopup="figbvdF2" rid-ob="figobbvdF2"><img class="small-thumb" src="/books/NBK1167/bin/bvd-Image002.gif" src-large="/books/NBK1167/bin/bvd-Image002.jpg" alt="Figure 2. " /></a><div class="icnblk_cntnt" id="figlgndbvdF2"><h4 id="bvd.F2"><a href="/books/NBK1167/figure/bvd.F2/?report=objectonly" target="object" rid-ob="figobbvdF2">Figure 2. </a></h4><p class="float-caption no_bottom_margin">Pseudohypopyon (Stage 3) </p></div></div><div class="iconblock whole_rhythm clearfix ten_col fig" id="figbvdF3" co-legend-rid="figlgndbvdF3"><a href="/books/NBK1167/figure/bvd.F3/?report=objectonly" target="object" title="Figure 3. " class="img_link icnblk_img figpopup" rid-figpopup="figbvdF3" rid-ob="figobbvdF3"><img class="small-thumb" src="/books/NBK1167/bin/bvd-Image003.gif" src-large="/books/NBK1167/bin/bvd-Image003.jpg" alt="Figure 3. " /></a><div class="icnblk_cntnt" id="figlgndbvdF3"><h4 id="bvd.F3"><a href="/books/NBK1167/figure/bvd.F3/?report=objectonly" target="object" rid-ob="figobbvdF3">Figure 3. </a></h4><p class="float-caption no_bottom_margin">Central scarring (Stage 4b) </p></div></div><p>The following clinical stages have been described, but it is important to note that the disease does not progress through each of these stages in every individual:</p><ul><li class="half_rhythm"><div><b>Stage 0.</b> Normal macula. Abnormal EOG</div></li><li class="half_rhythm"><div><b>Stage 1.</b> Retinal pigment epithelium (RPE) disruption in the macular region. Fluorescein angiogram (FA) shows window defects.</div></li><li class="half_rhythm"><div><b>Stage 2.</b> Circular, well-circumscribed, yellow-opaque, homogeneous yolk-like macular lesion (vitelliform lesion) (see <a class="figpopup" href="/books/NBK1167/figure/bvd.F1/?report=objectonly" target="object" rid-figpopup="figbvdF1" rid-ob="figobbvdF1">Figure 1</a>). FA reveals marked hypofluorescence in the zone covered by the lesion.</div></li><li class="half_rhythm"><div><b>Stage 2a.</b> Vitelliform lesion contents become less homogeneous to develop a "scrambled-egg" appearance. FA shows partial blockage of fluorescence with a non-homogeneous hyperfluorescence.</div></li><li class="half_rhythm"><div><b>Stage 3.</b> Pseudohypopyon phase (see <a class="figpopup" href="/books/NBK1167/figure/bvd.F2/?report=objectonly" target="object" rid-figpopup="figbvdF2" rid-ob="figobbvdF2">Figure 2</a>). The lesion develops a fluid level of a yellow-colored vitelline substance. FA shows inferior hypofluorescence from the blockage by the vitelline material, along with superior hyperfluorescent defects.</div></li><li class="half_rhythm"><div><b>Stage 4a.</b> Orange-red lesion with atrophic RPE and visibility of the choroid. FA shows hyperfluorescence without leakage.</div></li><li class="half_rhythm"><div><b>Stage 4b.</b> Fibrous scarring of the macula (see <a class="figpopup" href="/books/NBK1167/figure/bvd.F3/?report=objectonly" target="object" rid-figpopup="figbvdF3" rid-ob="figobbvdF3">Figure 3</a>). FA shows hyperfluorescence without leakage.</div></li><li class="half_rhythm"><div><b>Stage 4c.</b> Choroidal neovascularization with new vessels on the fibrous scar or appearance of subretinal hemorrhage. FA shows hyperfluorescence as a result of neovascularization and leakage.</div></li></ul><p><b>Electrophysiology</b></p><ul><li class="half_rhythm"><div>The electrooculogram (EOG) measures indirectly the standing potential of the eye:</div><ul><li class="half_rhythm"><div class="half_rhythm">A normal light peak / dark trough ratio (Arden ratio) is greater than 1.8. (Arden ratio decreases with age after the fourth decade; this value is not absolute.)</div></li><li class="half_rhythm"><div class="half_rhythm">In individuals with Best vitelliform macular dystrophy, the EOG is usually abnormal with a reduced light peak / dark trough ratio (Arden ratio) less than 1.5, most often between 1.0 and 1.3.</div><div class="half_rhythm">Note: Occasionally individuals with clinical findings of Best vitelliform macular dystrophy and a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>BEST1</i> have a normal EOG [<a class="bk_pop" href="#bvd.REF.testa.2008.1467">Testa et al 2008</a>].</div></li></ul></li><li class="half_rhythm"><div>The full-field electroretinogram (ERG) is normal. Foveal ERG or multifocal ERG reveals reduced central amplitudes [<a class="bk_pop" href="#bvd.REF.scholl.2002.1053">Scholl et al 2002</a>, <a class="bk_pop" href="#bvd.REF.palmowski.2003.145">Palmowski et al 2003</a>]. Abnormal multifocal ERG (mfERG) recordings match areas defined as clinically abnormal by optical coherence tomography (OCT) and retinal photography [<a class="bk_pop" href="#bvd.REF.glybina.2006.1593">Glybina &#x00026; Frank 2006</a>]. Scanning laser ophthalmoscope-evoked multifocal ERG (SLO-mfERG), used for topographic mapping of retinal function in individuals with Best vitelliform macular dystrophy [<a class="bk_pop" href="#bvd.REF.rudolph.2003.154">Rudolph &#x00026; Kalpadakis 2003</a>], reveals significantly reduced amplitudes in the macula.</div></li></ul><p><b>Color vision tests.</b> A significant proportion of individuals have anomalous color discrimination particularly in the protan axis. Color vision changes are nonspecific and non-diagnostic.</p><p><b>Optical coherence tomography (OCT).</b> This imaging approach can reveal the cross-sectional anatomy of the retina in individuals with Best vitelliform macular dystrophy [<a class="bk_pop" href="#bvd.REF.pianta.2003.203">Pianta et al 2003</a>, <a class="bk_pop" href="#bvd.REF.querques.2008.501">Querques et al 2008</a>]. OCT has defined normal retinal architecture or subtle changes in the outer retina in previtelliform clinical stages, splitting and elevation at the outer retina-retinal pigment epithelium complex in intermediate clinical stages, and thinning of the retina and retinal pigment epithelium in the atrophic clinical stage.</p><p><b>Fundus autofluorescence (AF).</b> This imaging modality has gained prominence over the past decade as it can detect metabolic changes in the retinal pigment epithelium (RPE) and photoreceptor layers that otherwise may not be detected in color fundus photos. Increased AF has been shown to correspond to the lesions seen in the fundus [<a class="bk_pop" href="#bvd.REF.boon.2008.2569">Boon et al 2008</a>].</p><p><b>Family history.</b> Family history is consistent with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> or <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> inheritance.</p></div><div id="bvd.Molecular_Genetic_Testing"><h3>Molecular Genetic Testing</h3><p><b>Gene.</b>
<i>BEST1</i> is the only <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> in which pathogenic variants are known to cause Best vitelliform macular dystrophy [<a class="bk_pop" href="#bvd.REF.marquardt.1998.1517">Marquardt et al 1998</a>, <a class="bk_pop" href="#bvd.REF.petrukhin.1998.241">Petrukhin et al 1998</a>, <a class="bk_pop" href="#bvd.REF.allikmets.1999.449">Allikmets et al 1999</a>, <a class="bk_pop" href="#bvd.REF.kr_mer.2000.286">Kr&#x000e4;mer et al 2000</a>, <a class="bk_pop" href="#bvd.REF.white.2000.301">White et al 2000</a>, <a class="bk_pop" href="#bvd.REF.seddon.2001.2060">Seddon et al 2001</a>].</p><p><b>Evidence for <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> heterogeneity.</b> Individuals with Best vitelliform macular dystrophy in whom no pathogenic variants in <i>BEST1</i> could be found have been reported.</p><ul><li class="half_rhythm"><div>This may result from the failure of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> to detect <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions and pathogenic variants in introns or untranslated 5' and 3' regions of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> [<a class="bk_pop" href="#bvd.REF.petrukhin.1998.241">Petrukhin et al 1998</a>, <a class="bk_pop" href="#bvd.REF.bakall.1999.383">Bakall et al 1999</a>, <a class="bk_pop" href="#bvd.REF.caldwell.1999.98">Caldwell et al 1999</a>, <a class="bk_pop" href="#bvd.REF.kr_mer.2000.286">Kr&#x000e4;mer et al 2000</a>, <a class="bk_pop" href="#bvd.REF.white.2000.301">White et al 2000</a>].</div></li><li class="half_rhythm"><div>It is possible that pathogenic variants in other genes can result in a similar <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. For example, <a class="bk_pop" href="#bvd.REF.boon.2007.1100">Boon et al [2007]</a> reported a patient in whom no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> was found in <i>BEST1</i> who had a sequence variant in the 5' untranslated region of <i>PRPH2</i> (<i>RDS</i>). A p.Pro210Arg pathogenic variant in <i>PRPH2</i> has been found in adult-onset vitelliform macular dystrophy [<a class="bk_pop" href="#bvd.REF.zhuk.2006.811">Zhuk &#x00026; Edwards 2006</a>].</div></li></ul><div id="bvd.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Best Vitelliform Macular Dystrophy</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1167/table/bvd.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__bvd.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_bvd.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="3" scope="col" colspan="1" headers="hd_h_bvd.T.molecular_genetic_testing_used_in_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_bvd.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="3" scope="col" colspan="1" headers="hd_h_bvd.T.molecular_genetic_testing_used_in_1_1_1_2" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_bvd.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="3" scope="col" colspan="1" headers="hd_h_bvd.T.molecular_genetic_testing_used_in_1_1_1_3" style="text-align:left;vertical-align:middle;">Allelic Variants Detected&#x000a0;<sup>2</sup></th><th id="hd_h_bvd.T.molecular_genetic_testing_used_in_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Variant Detection Frequency by Test Method&#x000a0;<sup>3</sup></th></tr><tr><th headers="hd_h_bvd.T.molecular_genetic_testing_used_in_1_1_1_4" id="hd_h_bvd.T.molecular_genetic_testing_used_in_1_1_2_1" colspan="2" scope="colgroup" rowspan="1" style="text-align:center;vertical-align:middle;">Family History</th></tr><tr><th headers="hd_h_bvd.T.molecular_genetic_testing_used_in_1_1_1_4 hd_h_bvd.T.molecular_genetic_testing_used_in_1_1_2_1" id="hd_h_bvd.T.molecular_genetic_testing_used_in_1_1_3_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Positive</th><th headers="hd_h_bvd.T.molecular_genetic_testing_used_in_1_1_1_4 hd_h_bvd.T.molecular_genetic_testing_used_in_1_1_2_1" id="hd_h_bvd.T.molecular_genetic_testing_used_in_1_1_3_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Negative</th></tr></thead><tbody><tr><td headers="hd_h_bvd.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>BEST1</i></td><td headers="hd_h_bvd.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>4</sup></td><td headers="hd_h_bvd.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence variants</td><td headers="hd_h_bvd.T.molecular_genetic_testing_used_in_1_1_1_4 hd_h_bvd.T.molecular_genetic_testing_used_in_1_1_2_1 hd_h_bvd.T.molecular_genetic_testing_used_in_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">96%&#x000a0;<sup>5</sup></td><td headers="hd_h_bvd.T.molecular_genetic_testing_used_in_1_1_1_4 hd_h_bvd.T.molecular_genetic_testing_used_in_1_1_2_1 hd_h_bvd.T.molecular_genetic_testing_used_in_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">50%-70%&#x000a0;<sup>6</sup></td></tr><tr><td headers="hd_h_bvd.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Deletion/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> analysis&#x000a0;<sup>7</sup></td><td headers="hd_h_bvd.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Partial or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications</td><td headers="hd_h_bvd.T.molecular_genetic_testing_used_in_1_1_1_4 hd_h_bvd.T.molecular_genetic_testing_used_in_1_1_2_1 hd_h_bvd.T.molecular_genetic_testing_used_in_1_1_3_1 hd_h_bvd.T.molecular_genetic_testing_used_in_1_1_3_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:middle;">Unknown; none reported&#x000a0;<sup>8</sup></td></tr><tr><td headers="hd_h_bvd.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Targeted analysis for pathogenic variants</td><td headers="hd_h_bvd.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.383G&#x0003e;C</td><td headers="hd_h_bvd.T.molecular_genetic_testing_used_in_1_1_1_4 hd_h_bvd.T.molecular_genetic_testing_used_in_1_1_2_1 hd_h_bvd.T.molecular_genetic_testing_used_in_1_1_3_1 hd_h_bvd.T.molecular_genetic_testing_used_in_1_1_3_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:middle;">Majority of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals in an extended Swedish kindred&#x000a0;<sup>9</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="bvd.TF.1.1"><p class="no_margin">See <a href="/books/NBK1167/#bvd.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="bvd.TF.1.2"><p class="no_margin">See <a href="#bvd.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants.</p></div></dd><dt>3. </dt><dd><div id="bvd.TF.1.3"><p class="no_margin">The ability of the test method used to detect a variant that is present in the indicated <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a></p></div></dd><dt>4. </dt><dd><div id="bvd.TF.1.4"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>5. </dt><dd><div id="bvd.TF.1.5"><p class="no_margin">Detects pathogenic variants in up to 96% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with a positive family history [<a class="bk_pop" href="#bvd.REF.kr_mer.2000.286">Kr&#x000e4;mer et al [2000]</a></p></div></dd><dt>6. </dt><dd><div id="bvd.TF.1.6"><p class="no_margin">In individuals with no family history of Best vitelliform macular dystrophy the variant detection rate ranges between 50% and 70% [<a class="bk_pop" href="#bvd.REF.kr_mer.2000.286">Kr&#x000e4;mer et al 2000</a>, <a class="bk_pop" href="#bvd.REF.white.2000.301">White et al 2000</a>].</p></div></dd><dt>7. </dt><dd><div id="bvd.TF.1.7"><p class="no_margin">Testing that identifies <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications not readily detectable by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of the coding and flanking <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> regions of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA; included in the variety of methods that may be used are: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and <a class="def" href="/books/n/gene/glossary/def-item/chromosomal-microarray/">chromosomal microarray</a> (CMA) that includes this gene/<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> segment.</p></div></dd><dt>8. </dt><dd><div id="bvd.TF.1.8"><p class="no_margin">No deletions or duplications in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> have been reported to cause Best vitelliform macular dystrophy.</p></div></dd><dt>9. </dt><dd><div id="bvd.TF.1.9"><p class="no_margin"><i>BEST1</i> c.383G&#x0003e;C (p.Trp93Cys) variant for individuals who can trace their ancestry to a large Swedish kindred ("<a class="def" href="/books/n/gene/glossary/def-item/pedigree/">pedigree</a> S1") [<a class="bk_pop" href="#bvd.REF.petrukhin.1998.241">Petrukhin et al 1998</a>]</p></div></dd></dl></div></div></div></div><div id="bvd.Testing_Strategy"><h3>Testing Strategy</h3><p><b>To confirm/establish the diagnosis in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Targeted analysis</b> for the c.383G&#x0003e;C <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is recommended for individuals of Swedish ancestry who are suspected of having Best vitelliform macular dystrophy. If this variant is not found, <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of the entire <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> may detect a pathogenic variant.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> One strategy for molecular diagnosis of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> suspected of having Best vitelliform macular dystrophy is <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of <i>BEST1</i>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Multigene panel.</b> For some probands, it may be appropriate to consider using an eye disorders <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> that includes <i>BEST1</i>. These panels vary by methods used and genes included; thus, the ability of a panel to detect a causative variant or variants in any given individual also varies.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul><p><b>Predictive testing</b> for at-risk asymptomatic adult family members (for clarification of genetic status) requires prior identification of the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) in the family.</p><p><b>Carrier testing for at-risk relatives</b> (in those rare cases where inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>) requires prior identification of the pathogenic variants in the family.</p><p><b>Prenatal diagnosis and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> (PGD)</b> for at-risk pregnancies require prior identification of the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) in the family.</p></div></div><div id="bvd.Clinical_Characteristics"><h2 id="_bvd_Clinical_Characteristics_">Clinical Characteristics</h2><div id="bvd.Clinical_Description"><h3>Clinical Description</h3><p>Best vitelliform macular dystrophy is a slowly progressive macular dystrophy with onset in childhood and sometimes in later teenage years. Retinal findings are not generally present at birth and typically do not manifest until ages five to ten years. Best vitelliform macular dystrophy is characterized by normal vision followed by decreased central visual acuity and metamorphopsia (<a class="figpopup" href="/books/NBK1167/table/bvd.T.stages_of_disease_progression_in_b/?report=objectonly" target="object" rid-figpopup="figbvdTstagesofdiseaseprogressioninb" rid-ob="figobbvdTstagesofdiseaseprogressioninb">Table 2</a>). Expression and age of onset are variable (<a class="figpopup" href="/books/NBK1167/table/bvd.T.age_and_disease_progression_in_bes/?report=objectonly" target="object" rid-figpopup="figbvdTageanddiseaseprogressioninbes" rid-ob="figobbvdTageanddiseaseprogressioninbes">Table 3</a>). Some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals remain asymptomatic, while others have significant visual impairment. Peripheral vision and dark adaptation remain normal.</p><p>Atypical phenotypic presentations in individuals with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>BEST1</i> have been described. Affected individuals may show multiple vitelliform lesions, lesions with fibrosis, or variable presentations within families. All <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have had an abnormal EOG; some have had an abnormal ERG [<a class="bk_pop" href="#bvd.REF.macdonald.2012.123">MacDonald et al 2012</a>, <a class="bk_pop" href="#bvd.REF.boon.2013.809">Boon et al 2013</a>].</p><p>The genetic or environmental factors that influence severity of disease are unknown.</p><div id="bvd.T.stages_of_disease_progression_in_b" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Stages of Disease Progression in Best Vitelliform Macular Dystrophy</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1167/table/bvd.T.stages_of_disease_progression_in_b/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__bvd.T.stages_of_disease_progression_in_b_lrgtbl__"><table><thead><tr><th id="hd_h_bvd.T.stages_of_disease_progression_in_b_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Stage</th><th id="hd_h_bvd.T.stages_of_disease_progression_in_b_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Signs</th></tr></thead><tbody><tr><td headers="hd_h_bvd.T.stages_of_disease_progression_in_b_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0 &#x00026; 1</td><td headers="hd_h_bvd.T.stages_of_disease_progression_in_b_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>No change in stage in 10 yrs</div></li><li class="half_rhythm"><div>Visual acuity of 20/20 in 75%</div></li></ul>
</td></tr><tr><td headers="hd_h_bvd.T.stages_of_disease_progression_in_b_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2 &#x00026; 3</td><td headers="hd_h_bvd.T.stages_of_disease_progression_in_b_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>For a large portion, advance in stage within 5-10 yrs</div></li><li class="half_rhythm"><div>Visual acuity of 20/40 or better in majority</div></li></ul>
</td></tr><tr><td headers="hd_h_bvd.T.stages_of_disease_progression_in_b_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4</td><td headers="hd_h_bvd.T.stages_of_disease_progression_in_b_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>No change in stage over 5 yrs for majority</div></li><li class="half_rhythm"><div>10% of 4a and 16% of 4b progress to stage 4c</div></li><li class="half_rhythm"><div>Visual acuity of 20/20 in 10%; 19% lose 2 lines or more in visual acuity over 8-10 yrs</div></li></ul>
</td></tr></tbody></table></div></div><div id="bvd.T.age_and_disease_progression_in_bes" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Age and Disease Progression in Best Vitelliform Macular Dystrophy</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1167/table/bvd.T.age_and_disease_progression_in_bes/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__bvd.T.age_and_disease_progression_in_bes_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_bvd.T.age_and_disease_progression_in_bes_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Age</th><th id="hd_h_bvd.T.age_and_disease_progression_in_bes_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Visual Acuity</th></tr></thead><tbody><tr><td headers="hd_h_bvd.T.age_and_disease_progression_in_bes_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02264;40 yrs</td><td headers="hd_h_bvd.T.age_and_disease_progression_in_bes_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>In ~75%, &#x02265;20/40 in better eye</div></li><li class="half_rhythm"><div>In ~66%, &#x0003c;20/40 in worse eye</div></li></ul>
</td></tr><tr><td headers="hd_h_bvd.T.age_and_disease_progression_in_bes_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02265;50 yrs</td><td headers="hd_h_bvd.T.age_and_disease_progression_in_bes_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>In ~50%, 20/70 in better eye</div></li><li class="half_rhythm"><div>In 100%, &#x02264;20/100 in worse eye</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">From <a class="bk_pop" href="#bvd.REF.miller.1976.252">Miller et al [1976]</a>, <a class="bk_pop" href="#bvd.REF.mohler.1981.688">Mohler &#x00026; Fine [1981]</a>, <a class="bk_pop" href="#bvd.REF.fishman.1993.1665">Fishman et al [1993]</a>, <a class="bk_pop" href="#bvd.REF.marano.2000.760">Marano et al [2000]</a></p></div></dd></dl></div></div></div><p><b>Histopathology.</b> Light and electron microscopy show abnormal accumulation of lipofuscin granules within the RPE throughout the macula and also in the remainder of the retina.</p></div><div id="bvd.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Genotype-<a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> correlations have not been demonstrated.</p><p>Minimal information correlates individual pathogenic variants to a specific stage of disease or degree of visual impairment. However, <a class="bk_pop" href="#bvd.REF.eksandh.2001.107">Eksandh et al [2001]</a> describe a family with a p.Val89Ala substitution and a <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of late-onset visual failure (age 40-50 years).</p><p><a class="bk_pop" href="#bvd.REF.mullins.2005.1588">Mullins et al [2005]</a> describe a family with a p.Tyr227Asn substitution and a <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of late-onset small vitelliform lesions.</p><p>Three families with <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> pathogenic variants and <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> inheritance of Best vitelliform macular dystrophy were reported [<a class="bk_pop" href="#bvd.REF.bitner.2011.5332">Bitner et al 2011</a>, <a class="bk_pop" href="#bvd.REF.iannaccone.2011.211">Iannaccone et al 2011</a>, <a class="bk_pop" href="#bvd.REF.zhao.2012.866">Zhao et al 2012</a>]. Six children from three different families have been found to have <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>BEST1</i>. Four of the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals had multiple vitelliform lesions. Two individuals were <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the c.1415delT variant, one individual was a compound <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a> for p.Arg141Ser and p.Arg141His, and three individuals were compound heterozygotes for p.Leu41Pro and p.Ile201Thr variants. Heterozygous carriers did not develop disease.</p></div><div id="bvd.Penetrance"><h3>Penetrance</h3><p>Best vitelliform macular dystrophy shows generally complete <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>, especially when the EOG is used as evidence of clinical expression. Evidence for non-penetrance has been reported.</p></div><div id="bvd.Anticipation"><h3>Anticipation</h3><p>Genetic <a class="def" href="/books/n/gene/glossary/def-item/anticipation/">anticipation</a> has not been reported in Best vitelliform macular dystrophy.</p></div><div id="bvd.Nomenclature"><h3>Nomenclature</h3><p>The following terms are in use:</p><ul><li class="half_rhythm"><div>Best disease</div></li><li class="half_rhythm"><div>Vitelliform macular dystrophy, early onset</div></li><li class="half_rhythm"><div>Vitelliform macular dystrophy, juvenile onset</div></li><li class="half_rhythm"><div>Vitelliform macular dystrophy, adult onset</div></li><li class="half_rhythm"><div>Macular degeneration, polymorphic vitelline</div></li></ul></div><div id="bvd.Prevalence"><h3>Prevalence</h3><p>Best vitelliform macular dystrophy is a rare disorder. The prevalence is unknown.</p></div></div><div id="bvd.Genetically_Related_Allelic_Disorder"><h2 id="_bvd_Genetically_Related_Allelic_Disorder_">Genetically Related (Allelic) Disorders</h2><p>Pathogenic variants in <i>BEST1</i> have been found in:</p><ul><li class="half_rhythm"><div>Eight individuals with bull's-eye maculopathy [<a class="bk_pop" href="#bvd.REF.seddon.2001.2060">Seddon et al 2001</a>];</div></li><li class="half_rhythm"><div>Two individuals with adult vitelliform macular dystrophy (AVMD) [<a class="bk_pop" href="#bvd.REF.kr_mer.2000.286">Kr&#x000e4;mer et al 2000</a>] (see also <a href="#bvd.Differential_Diagnosis">Differential Diagnosis</a>);</div></li><li class="half_rhythm"><div>Families with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> vitreoretinochoroidopathy (ADVIRC) associated with nanophthalmos [<a class="bk_pop" href="#bvd.REF.yardley.2004.3683">Yardley et al 2004</a>]. Patients with ADVIRC have nanophthalmos, microcornea, angle closure glaucoma, <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> cataract (posterior subcapsular), and a retinal dystrophy. The retinal dystrophy is characterized by peripheral retina pigment, white preretinal opacities, apparent cystoid macular edema, retinal neovascularization, choroid atrophy, and a fibrillar condensation of the vitreous. The ERG and EOG are abnormal. ADVIRC is caused by distinct pathogenic variants in <i>BEST1</i> that alter pre-<a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> [<a class="bk_pop" href="#bvd.REF.burgess.2009.620">Burgess et al 2009</a>].</div></li><li class="half_rhythm"><div>Individuals with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> bestrophinopathy (ARB):</div><ul><li class="half_rhythm"><div>Pathogenic variants in both alleles of <i>BEST1</i> (<a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> mutation) that result in a more severe retinopathy than Best vitelliform macular dystrophy have been seen in individuals of Swedish ancestry who have two <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants [<a class="bk_pop" href="#bvd.REF.schatz.2006.51">Schatz et al 2006</a>].</div></li><li class="half_rhythm"><div>Similarly, an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> bestrophinopathy [<a class="bk_pop" href="#bvd.REF.burgess.2008.19">Burgess et al 2008</a>] has been identified in individuals with a cone-rod dystrophy, an abnormal ERG, and a markedly reduced Arden ratio of the EOG. Affected individuals have white subretinal deposits and macular subretinal fluid which may suggest the diagnosis. Heterozygotes, who have either a <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> in one <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> or a <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variant, do not have clinical signs or electrophysiologic abnormalities.</div></li></ul></li></ul></div><div id="bvd.Differential_Diagnosis"><h2 id="_bvd_Differential_Diagnosis_">Differential Diagnosis</h2><p>Best vitelliform macular dystrophy is readily recognized by its distinct macular lesion. The following retinopathies may be confused with Best vitelliform macular dystrophy [<a class="bk_pop" href="#bvd.REF.allikmets.1999.449">Allikmets et al 1999</a>, <a class="bk_pop" href="#bvd.REF.kr_mer.2000.286">Kr&#x000e4;mer et al 2000</a>, <a class="bk_pop" href="#bvd.REF.white.2000.301">White et al 2000</a>, <a class="bk_pop" href="#bvd.REF.seddon.2001.2060">Seddon et al 2001</a>]:</p><ul><li class="half_rhythm"><div><b>Adult vitelliform macular dystrophy (AVMD).</b> This <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> disorder, characterized by the presence of bilateral, small, circular, yellow, symmetrical, subretinal lesions with drusen-like deposits, affects mainly middle-aged individuals. The funduscopic findings can easily be mistaken for Best vitelliform macular dystrophy, but the EOG is normal or only slightly reduced in these individuals. Pathogenic variants in <i>PRPH2</i> (<i>RDS</i>) (which encodes the protein peripherin) and <i>BEST1</i> have been found in a small number of individuals with AVMD, demonstrating the genetic heterogeneity of the disorder [<a class="bk_pop" href="#bvd.REF.renner.2004.929">Renner et al 2004</a>, <a class="bk_pop" href="#bvd.REF.yu.2006.4956">Yu et al 2006</a>, <a class="bk_pop" href="#bvd.REF.zhuk.2006.811">Zhuk &#x00026; Edwards 2006</a>]. AVMD shows significant phenotypic overlap with Best vitelliform macular dystrophy. Using OCT, <a class="bk_pop" href="#bvd.REF.hayami.2003.53">Hayami et al [2003]</a> found that the structure of the vitelliform lesions in the two disorders were similar.</div></li><li class="half_rhythm"><div><b>Age-related macular degeneration (AMD).</b> This common disorder is characterized by drusen, RPE disruption, and choroidal neovascularization. Multiple lines of evidence indicate that AMD has a <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> component. Pathogenic variants in a number of genes (including <i>CFH</i>, <i>CFB</i>, <i>ABCA4</i>, <i>TIMP3</i>, and <i>EFEMP1</i>) have been associated with AMD [<a class="bk_pop" href="#bvd.REF.patel.2008.768">Patel et al 2008</a>]. Pathogenic variants in <i>BEST1</i> are rare in cases of AMD [<a class="bk_pop" href="#bvd.REF.allikmets.1999.449">Allikmets et al 1999</a>, <a class="bk_pop" href="#bvd.REF.kr_mer.2000.286">Kr&#x000e4;mer et al 2000</a>, <a class="bk_pop" href="#bvd.REF.lotery.2000.1291">Lotery et al 2000</a>, <a class="bk_pop" href="#bvd.REF.seddon.2001.2060">Seddon et al 2001</a>].</div></li><li class="half_rhythm"><div><b>Bull's-eye maculopathy.</b> This descriptive clinical diagnosis is typified by an annular region with depigmentation of central RPE in the macula [<a class="bk_pop" href="#bvd.REF.seddon.2001.2060">Seddon et al 2001</a>]. The <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> can be seen in individuals with cone dystrophy, cone-rod dystrophy, Stargardt disease, chloroquine maculopathy, and other maculopathies. <a class="bk_pop" href="#bvd.REF.seddon.2001.2060">Seddon et al [2001]</a> found one individual with a bull's-eye maculopathy who had a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>BEST1</i>.</div></li></ul></div><div id="bvd.Management"><h2 id="_bvd_Management_">Management</h2><div id="bvd.Evaluations_Following_Initial_Diagno"><h3>Evaluations Following Initial Diagnosis</h3><p>To determine the stage of disease and needs in an individual diagnosed with Best vitelliform macular dystrophy, ophthalmologic examination should be performed. Medical genetics consultation may also be considered.</p></div><div id="bvd.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Low vision aids provide benefit for those individuals with significant deterioration in visual acuity.</p><p>Stage 4c fundus lesions or choroidal neovascularization and hemorrhage can be managed by direct laser photocoagulation. <a class="bk_pop" href="#bvd.REF.marano.2000.760">Marano et al [2000]</a> suggested a conservative approach in the treatment of choroidal neovascularization based on two individuals with Best vitelliform macular dystrophy whose visual acuity improved. No clinical trials comparing the efficacy of laser photocoagulation to conservative treatment have been conducted.</p><p>Anti-VEGF (vascular endothelial growth factor) agents are the standard treatment for individuals with subfoveal choroidal neovascularization (CNV). <a class="bk_pop" href="#bvd.REF.leu.2007.1723">Leu et al [2007]</a> injected intravitreal bevacizumab in a 13 year-old with Best vitelliform macular dystrophy and CNV, hastening visual recovery and regression of the CNV. Intravitreal ranibizumab has also been used with success [<a class="bk_pop" href="#bvd.REF.querques.2009.2960">Querques et al 2009</a>]. There are no reports on the use of aflibercept. Long-term follow up of these <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals is unknown. There are currently no clinical trials to demonstrate the effectiveness of anti-VEGF agents on CNV in Best vitelliform macular dystrophy.</p><p><a class="bk_pop" href="#bvd.REF.andrade.2003.1179">Andrade et al [2003]</a> performed photodynamic therapy (PDT) using verteporfin for CNV on one person with Best vitelliform macular dystrophy. The CNV regressed and the subretinal hemorrhage resolved. The authors suggested that PDT may be an option for treatment of CNV in Best vitelliform macular dystrophy.</p><p>Genetic counseling and occupational counseling should be offered.</p></div><div id="bvd.Surveillance"><h3>Surveillance</h3><p>Ophthalmologic examination should be performed annually to monitor the progression of the fundus lesions; in childhood, annual examinations are important in preventing the development of amblyopia. Affected individuals should be advised to see their ophthalmologist in the event of decreased vision or metamorphopsia, which could be signs of CNV.</p></div><div id="bvd.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Cessation of smoking helps prevent neovascularization of the retina [<a class="bk_pop" href="#bvd.REF.clemons.2005.533">Clemons et al 2005</a>].</p></div><div id="bvd.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#bvd.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="bvd.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="https://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="bvd.Genetic_Counseling"><h2 id="_bvd_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="bvd.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Best vitelliform macular dystrophy is most commonly inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. However, three families with <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> pathogenic variants and <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> inheritance have been described [<a class="bk_pop" href="#bvd.REF.bitner.2011.5332">Bitner et al 2011</a>, <a class="bk_pop" href="#bvd.REF.iannaccone.2011.211">Iannaccone et al 2011</a>, <a class="bk_pop" href="#bvd.REF.zhao.2012.866">Zhao et al 2012</a>].</p></div><div id="bvd.Risk_to_Family_Members__Autosomal_Do"><h3>Risk to Family Members &#x02014; Autosomal Dominant Inheritance</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Most individuals diagnosed with Best vitelliform macular dystrophy have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent.</div></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with Best vitelliform macular dystrophy may have the disorder as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#bvd.REF.apushkin.2006.887">Apushkin et al 2006</a>, <a class="bk_pop" href="#bvd.REF.li.2006.408">Li et al 2006</a>, <a class="bk_pop" href="#bvd.REF.marchant.2007.e70">Marchant et al 2007</a>, <a class="bk_pop" href="#bvd.REF.atchaneeyasakul.2008.139">Atchaneeyasakul et al 2008</a>, <a class="bk_pop" href="#bvd.REF.testa.2008.1467">Testa et al 2008</a>]. The proportion of cases caused by a <i>de novo</i> pathogenic variant is unknown.</div></li><li class="half_rhythm"><div>Recommendations for the evaluation of parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> include funduscopic examination. Given that the fundus may appear normal in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, an EOG or <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (if the pathogenic variant in the family has been identified) can be definitive in the diagnosis of the disease [<a class="bk_pop" href="#bvd.REF.white.2000.301">White et al 2000</a>]. The disease may occur in <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases (i.e., a single occurrence in a family) [<a class="bk_pop" href="#bvd.REF.palomba.2000.260">Palomba et al 2000</a>].</div></li></ul><p>Note: Although most individuals diagnosed with Best vitelliform macular dystrophy have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent, the family history may appear to be negative because of failure to recognize the disorder in family members.</p><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The risk to the sibs depends on the genetic status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents.</div></li><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or has the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the risk to the sibs is 50%.</div></li><li class="half_rhythm"><div>When the parents are clinically unaffected and do not have the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the risk to the sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> appears to be low.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in DNA extracted from the leukocytes of either parent, two possible explanations are <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent or a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant in the proband. Although no instances of germline mosaicism have been reported, it remains a possibility.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual with Best vitelliform macular dystrophy has a 50% chance of inheriting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to other family members depends on the status of the proband's parents: if a parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, his or her family members are at risk.</p></div><div id="bvd.Risk_to_Family_Members__Autosomal_Re"><h3>Risk to Family Members &#x02014; Autosomal Recessive Inheritance</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes and therefore carry one mutated <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>.</div></li><li class="half_rhythm"><div>To date, carriers of the variants associated with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> Best vitelliform macular dystrophy are clinically unaffected [<a class="bk_pop" href="#bvd.REF.zhao.2012.866">Zhao et al 2012</a>].</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Once an at-risk sib is known to be unaffected, the risk of his/her being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> is 2/3.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) of variants known to be associated with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> Best vitelliform macular dystrophy are asymptomatic.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The offspring of an individual with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> Best vitelliform macular dystrophy are obligate heterozygotes for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) of variants known to be associated with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> Best vitelliform macular dystrophy are asymptomatic.</div></li></ul><p><b>Other family members of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each sib of the proband's parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>.</p></div><div id="bvd.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk family members is possible if the pathogenic variants in the family are known.</p></div><div id="bvd.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p><b>Specific risk issues.</b> The age of onset, clinical manifestations of the disease, and degree of functional impairment in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual cannot be predicted.</p><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> condition has the pathogenic variant or clinical evidence of the disorder, it is likely that the proband has a <i>de novo</i> pathogenic variant. However, possible non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or at risk.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="bvd.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for Best vitelliform macular dystrophy are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="bvd.Resources"><h2 id="_bvd_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Association for Macular Diseases</b></div><div>210 East 64th Street</div><div>8th Floor</div><div>New York NY 10065</div><div><b>Phone:</b> 212-605-3719</div><div><b>Fax:</b> 212-605-3795</div><div><b>Email:</b> association@retinal-research.org</div><div><a href="http://www.macula.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.macula.org</a></div></li><li class="half_rhythm"><div><b>Macular Degeneration Foundation</b></div><div>PO Box 531313</div><div>Henderson NV 89053</div><div><b>Phone:</b> 888-633-3937 (toll-free); 702-450-2908</div><div><b>Fax:</b> 702-450-3396</div><div><b>Email:</b> liz@eyesight.org</div><div><a href="http://www.eyesight.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.eyesight.org</a></div></li><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=Best%20vitelliform%20macular%20dystrophy&#x00026;parent=Genetic%20Syndromes&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Best vitelliform macular dystrophy</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition=vitelliformmaculardystrophy" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Vitelliform macular dystrophy</a></div></li><li class="half_rhythm"><div><b>NCBI Genes and Disease</b></div><div><a href="/books/NBK22187/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Best disease</a></div></li><li class="half_rhythm"><div><b>Foundation Fighting Blindness</b></div><div>7168 Columbia Gateway Drive</div><div>Suite 100</div><div>Columbia MD 21046</div><div><b>Phone:</b> 800-683-5555 (toll-free); 800-683-5551 (toll-free TDD); 410-423-0600</div><div><b>Email:</b> info@fightblindness.org</div><div><a href="https://www.fightingblindness.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.fightingblindness.org</a></div></li><li class="half_rhythm"><div><b>eyeGENE - National Ophthalmic Disease Genotyping Network Registry</b></div><div><b>Phone:</b> 301-435-3032</div><div><b>Email:</b> eyeGENEinfo@nei.nih.gov</div><div><a href="https://eyegene.nih.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.nei.nih.gov/eyegene</a></div></li></ul></div><div id="bvd.Molecular_Genetics"><h2 id="_bvd_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="bvd.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Best Vitelliform Macular Dystrophy: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1167/table/bvd.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__bvd.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_bvd.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_bvd.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_bvd.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_bvd.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_bvd.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_bvd.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_bvd.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/7439" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>BEST1</i></a></td><td headers="hd_b_bvd.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=7439" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">11q12<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_bvd.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/O76090" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bestrophin-1</a></td><td headers="hd_b_bvd.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://databases.lovd.nl/shared/genes/BEST1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BEST1 gene homepage</a></td><td headers="hd_b_bvd.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=BEST1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BEST1</a></td><td headers="hd_b_bvd.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=BEST1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BEST1</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="bvd.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="bvd.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Best Vitelliform Macular Dystrophy (<a href="/omim/153700,607854" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1167/table/bvd.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__bvd.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/153700" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">153700</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MACULAR DYSTROPHY, VITELLIFORM, 2; VMD2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/607854" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">607854</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BESTROPHIN 1; BEST1</td></tr></tbody></table></div></div><div id="bvd.Molecular_Genetic_Pathogenesis"><h3>Molecular Genetic Pathogenesis</h3><p><a class="bk_pop" href="#bvd.REF.sun.2002.4008">Sun et al [2002]</a> showed the existence of a new chloride channel family that includes Best vitelliform macular dystrophy. They used heterologous expression studies to demonstrate that human, <i>Drosophila</i>, and <i>C. elegans</i> bestrophin homologs form oligomeric chloride channels. Human bestrophin was sensitive to intracellular calcium. Fifteen pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants were associated with reduced or abolished membrane current. <a class="bk_pop" href="#bvd.REF.marmorstein.2002.30591">Marmorstein et al [2002]</a> demonstrated that bestrophin undergoes dephosphorylation by a protein phosphatase. This finding suggests that bestrophin participates in a signal transduction pathway that may be related to the modulation of the light peak on the EOG. Despite the current genetic and molecular information of Best vitelliform macular dystrophy, the pathogenesis remains unexplained.</p><p><b>Benign variants.</b>
<i>BEST1</i> has 11 exons. Most of the frequent polymorphisms and rare variants occur within non-coding regions or do not result in an amino acid substitution [<a class="bk_pop" href="#bvd.REF.white.2000.301">White et al 2000</a>]. <a class="bk_pop" href="#bvd.REF.allikmets.1999.449">Allikmets et al [1999]</a> also described three rare amino acid substitutions of <a class="def" href="/books/n/gene/glossary/def-item/unknown-significance/">unknown significance</a> located at the C-terminus (p.Glu525Ala, p.Glu557Lys, and p.Thr561Ala).</p><p><b>Pathogenic variants.</b> A spectrum of <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants have been identified [<a class="bk_pop" href="#bvd.REF.marquardt.1998.1517">Marquardt et al 1998</a>, <a class="bk_pop" href="#bvd.REF.petrukhin.1998.241">Petrukhin et al 1998</a>, <a class="bk_pop" href="#bvd.REF.allikmets.1999.449">Allikmets et al 1999</a>, <a class="bk_pop" href="#bvd.REF.bakall.1999.383">Bakall et al 1999</a>, <a class="bk_pop" href="#bvd.REF.kr_mer.2000.286">Kr&#x000e4;mer et al 2000</a>, <a class="bk_pop" href="#bvd.REF.white.2000.301">White et al 2000</a>, <a class="bk_pop" href="#bvd.REF.seddon.2001.2060">Seddon et al 2001</a>, <a class="bk_pop" href="#bvd.REF.kr_mer.2003.418">Kr&#x000e4;mer et al 2003</a>]. <a class="bk_pop" href="#bvd.REF.white.2000.301">White et al [2000]</a> reviewed 48 reported pathogenic variants in <i>BEST1</i>: 45 missense variants, two deletions, and one <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variant. The majority of the variants occur in the first 50% of the protein, in four unique clusters (<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 2, 4, 6, and 8), suggesting possible regions of functional importance [<a class="bk_pop" href="#bvd.REF.white.2000.301">White et al 2000</a>]. (For more information, see <a href="/books/NBK1167/#bvd.molgen.TA">Table A. Genes and Databases</a>.)</p><p>One <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> was reported by <a class="bk_pop" href="#bvd.REF.caldwell.1999.98">Caldwell et al [1999]</a> involving two base pairs that led to a shift in the reading frame and truncation of the protein at amino acid 513. A <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variant affecting the donor site of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 5 was reported by <a class="bk_pop" href="#bvd.REF.kr_mer.2000.286">Kr&#x000e4;mer et al [2000]</a>.</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Bestrophin has 585 amino acids and a size of 68 kd [<a class="bk_pop" href="#bvd.REF.petrukhin.1998.241">Petrukhin et al 1998</a>]. The hydropathy profile predicts at least four putative transmembrane domains. Bestrophin has been found to be highly expressed by the RPE and was localized to the basolateral plasma membrane [<a class="bk_pop" href="#bvd.REF.marmorstein.2000.12758">Marmorstein et al 2000</a>]. Bestrophin functions either as a chloride channel or as a regulator of voltage-gated calcium channels in the RPE [<a class="bk_pop" href="#bvd.REF.hartzell.2008.639">Hartzell et al 2008</a>, <a class="bk_pop" href="#bvd.REF.yu.2008.5660">Yu et al 2008</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Pathogenic variants in <i>BEST1</i> alter the function of bestrophin and ion transport by the RPE, resulting in the accumulation of fluid between the RPE and the photoreceptors [<a class="bk_pop" href="#bvd.REF.qu.2006.5411">Qu et al 2006</a>, <a class="bk_pop" href="#bvd.REF.yu.2007.4694">Yu et al 2007</a>, <a class="bk_pop" href="#bvd.REF.hartzell.2008.639">Hartzell et al 2008</a>].</p><p>Note that carriers of variants found to cause AR disease are asymptomatic [<a class="bk_pop" href="#bvd.REF.zhao.2012.866">Zhao et al 2012</a>]. This is postulated to be due to the fact that the causative variants, when <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a>, allow the protein to retain a sufficient level of functioning as an ion channel or an ion channel regulator.</p></div></div><div id="bvd.References"><h2 id="_bvd_References_">References</h2><div id="bvd.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.allikmets.1999.449">Allikmets R, Seddon JM, Bernstein PS, Hutchinson A, Atkinson A, Sharma S, Gerrard B, Li W, Metzker ML, Wadelius C, Caskey CT, Dean M, Petrukhin K. Evaluation of the Best disease gene in patients with age-related macular degeneration and other maculopathies. <span><span class="ref-journal">Hum Genet. </span>1999;<span class="ref-vol">104</span>:449–53.</span> [<a href="/pubmed/10453731" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10453731</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.andrade.2003.1179">Andrade RE, Farah ME, Costa RA. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in best disease. <span><span class="ref-journal">Am J Ophthalmol. </span>2003;<span class="ref-vol">136</span>:1179–81.</span> [<a href="/pubmed/14644242" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14644242</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.apushkin.2006.887">Apushkin MA, Fishman GA, Taylor CM, Stone EM. Novel de novo mutation in a patient with Best macular dystrophy. <span><span class="ref-journal">Arch Ophthalmol. </span>2006;<span class="ref-vol">124</span>:887–9.</span> [<a href="/pubmed/16769844" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16769844</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.atchaneeyasakul.2008.139">Atchaneeyasakul LO, Jinda W, Sakolsatayadorn N, Trinavarat A, Ruangvoravate N, Thanasombatskul N, Thongnoppakhun W, Limwongse C. Mutation analysis of the VMD2 gene in Thai families with Best macular dystrophy. <span><span class="ref-journal">Ophthalmic Genet. </span>2008;<span class="ref-vol">29</span>:139–44.</span> [<a href="/pubmed/18766995" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18766995</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.bakall.1999.383">Bakall B, Marknell T, Ingvast S, Koisti MJ, Sandgren O, Li W, Bergen AA, Andreasson S, Rosenberg T, Petrukhin K, Wadelius C. The mutation spectrum of the bestrophin protein &#x02014; functional implications. <span><span class="ref-journal">Hum Genet. </span>1999;<span class="ref-vol">104</span>:383–9.</span> [<a href="/pubmed/10394929" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10394929</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.bitner.2011.5332">Bitner H, Mizrahi-Meissonnier L, Griefner G, Erdinest I, Sharon D, Banin E. A homozygous frameshift mutation in BEST1 causes the classical form of Best disease in an autosomal recessive mode. <span><span class="ref-journal">Invest Ophthalmol Vis Sci. </span>2011;<span class="ref-vol">52</span>:5332–8.</span> [<a href="/pubmed/21467170" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21467170</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.boon.2007.1100">Boon CJ, Klevering BJ, den Hollander AI, Zonneveld MN, Theelen T, Cremers FP, Hoyng CB. Clinical and genetic heterogeneity in multifocal vitelliform dystrophy. <span><span class="ref-journal">Arch Ophthalmol. </span>2007;<span class="ref-vol">125</span>:1100–6.</span> [<a href="/pubmed/17698758" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17698758</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.boon.2008.2569">Boon CJ, Klevering BJ, Keunen JE, Hoyng CB, Theelen T. Fundus fluorescence imaging of retinal dystrophies. <span><span class="ref-journal">Vision Res. </span>2008;<span class="ref-vol">48</span>:2569–77.</span> [<a href="/pubmed/18289629" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18289629</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.burgess.2009.620">Burgess R, MacLaren RE, Davidson AE, Urquhart JE, Holder GE, Robson AG, Moore AT, Keefe RO, Black GC, Manson FD. ADVIRC is caused by distinct mutations in BEST1 that alter pre-mRNA splicing. <span><span class="ref-journal">J Med Genet. </span>2009;<span class="ref-vol">46</span>:620–5.</span> [<a href="/pubmed/18611979" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18611979</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.boon.2013.809">Boon CJ, van den Born LI, Visser L, Keunen JE, Bergen AA, Booij JC, Riemslag FC, Florijn RJ, van Schooneveld MJ. Autosomal recessive bestrophinopathy: differential diagnosis and treatment options. <span><span class="ref-journal">Ophthalmology. </span>2013;<span class="ref-vol">120</span>:809–20.</span> [<a href="/pubmed/23290749" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23290749</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.burgess.2008.19">Burgess R, Millar ID, Leroy BP, Urquhart JE, Fearon IM, De Baere E, Brown PD, Robson AG, Wright GA, Kestelyn P, Holder GE, Webster AR, Manson FD, Black GC. Biallelic mutation of BEST1 causes a distinct retinopathy in humans. <span><span class="ref-journal">Am J Hum Genet. </span>2008;<span class="ref-vol">82</span>:19–31.</span> [<a href="/pmc/articles/PMC2253971/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2253971</span></a>] [<a href="/pubmed/18179881" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18179881</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.caldwell.1999.98">Caldwell GM, Kakuk LE, Griesinger IB, Simpson SA, Nowak NJ, Small KW, Maumenee IH, Rosenfeld PJ, Sieving PA, Shows TB, Ayyagari R. Bestrophin gene mutations in patients with Best vitelliform macular dystrophy. <span><span class="ref-journal">Genomics. </span>1999;<span class="ref-vol">58</span>:98–101.</span> [<a href="/pubmed/10331951" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10331951</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.clemons.2005.533">Clemons TE, Milton RC, Klein R, Seddon JM, Ferris FL 3rd, et al.  Risk factors for the incidence of advanced age-related macular degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. <span><span class="ref-journal">Ophthalmology. </span>2005;<span class="ref-vol">112</span>:533–9.</span> [<a href="/pmc/articles/PMC1513667/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1513667</span></a>] [<a href="/pubmed/15808240" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15808240</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.eksandh.2001.107">Eksandh L, Bakall B, Bauer B, Wadelius C, Andr&#x000e9;asson S. Best's vitelliform macular dystrophy caused by a new mutation (Val89Ala) in the VMD2 gene. <span><span class="ref-journal">Ophthalmic Genet. </span>2001;<span class="ref-vol">22</span>:107–15.</span> [<a href="/pubmed/11449320" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11449320</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.fishman.1993.1665">Fishman GA, Baca W, Alexander KR, Derlacki DJ, Glenn AM, Viana M. Visual acuity in patients with best vitelliform macular dystrophy. <span><span class="ref-journal">Ophthalmology. </span>1993;<span class="ref-vol">100</span>:1665–70.</span> [<a href="/pubmed/8233392" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8233392</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.glybina.2006.1593">Glybina IV, Frank RN. Localization of multifocal electroretinogram abnormalities to the lesion site: findings in a family with Best disease. <span><span class="ref-journal">Arch Ophthalmol. </span>2006;<span class="ref-vol">124</span>:1593–600.</span> [<a href="/pubmed/17102007" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17102007</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.hartzell.2008.639">Hartzell HC, Qu Z, Yu K, Xiao Q, Chien LT. Molecular physiology of bestrophins: multifunctional membrane proteins linked to best disease and other retinopathies. <span><span class="ref-journal">Physiol Rev. </span>2008;<span class="ref-vol">88</span>:639–72.</span> [<a href="/pubmed/18391176" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18391176</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.hayami.2003.53">Hayami M, Decock C, Brabant P, Van Kerckhoven W, Lafaut BA, De Laey JJ. Optical coherence tomography of adult-onset vitelliform dystrophy. <span><span class="ref-journal">Bull Soc Belge Ophtalmol. </span>2003;<span class="ref-vol">289</span>:53–61.</span> [<a href="/pubmed/14619630" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14619630</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.iannaccone.2011.211">Iannaccone A, Kerr NC, Kinnick TR, Calzada JI, Stone EM. Autosomal recessive best vitelliform macular dystrophy: report of a family and management of early-onset neovascular complications. <span><span class="ref-journal">Arch Ophthalmol. </span>2011;<span class="ref-vol">129</span>:211–7.</span> [<a href="/pubmed/21320969" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21320969</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.kr_mer.2003.418">Kr&#x000e4;mer F, Mohr N, Kellner U, Rudolph G, Weber BH. Ten novel mutations in VMD2 associated with Best macular dystrophy (BMD). <span><span class="ref-journal">Hum Mutat. </span>2003;<span class="ref-vol">22</span>:418.</span> [<a href="/pubmed/14517959" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14517959</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.kr_mer.2000.286">Kr&#x000e4;mer F, White K, Pauleikhoff D, Gehrig A, Passmore L, Rivera A, Rudolph G, Kellner U, Andrassi M, Lorenz B, Rohrschneider K, Blankenagel A, Jurklies B, Schilling H, Sch&#x000fc;tt F, Holz FG, Weber BH. Mutations in the VMD2 gene are associated with juvenile-onset vitelliform macular dystrophy (Best disease) and adult vitelliform macular dystrophy but not age-related macular degeneration. <span><span class="ref-journal">Eur J Hum Genet. </span>2000;<span class="ref-vol">8</span>:286–92.</span> [<a href="/pubmed/10854112" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10854112</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.leu.2007.1723">Leu J, Schrage NF, Degenring RF. Choroidal neovascularisation secondary to Best's disease in a 13-year-old boy treated by intravitreal bevacizumab. <span><span class="ref-journal">Graefes Arch Clin Exp Ophthalmol. </span>2007;<span class="ref-vol">245</span>:1723–5.</span> [<a href="/pubmed/17605026" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17605026</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.lotery.2000.1291">Lotery AJ, Munier FL, Fishman GA, Weleber RG, Jacobson SG, Affatigato LM, Nichols BE, Schorderet DF, Sheffield VC, Stone EM. Allelic variation in the VMD2 gene in best disease and age-related macular degeneration. <span><span class="ref-journal">Invest Ophthalmol Vis Sci. </span>2000;<span class="ref-vol">41</span>:1291–6.</span> [<a href="/pubmed/10798642" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10798642</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.li.2006.408">Li Y, Wang G, Dong B, Sun X, Turner MJ, Kamaya S, Zhang K. A novel mutation of the VMD2 gene in a Chinese family with best vitelliform macular dystrophy. <span><span class="ref-journal">Ann Acad Med Singapore. </span>2006;<span class="ref-vol">35</span>:408–10.</span> [<a href="/pubmed/16865191" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16865191</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.macdonald.2012.123">MacDonald IM, Gudiseva HV, Villanueva A, Greve M, Caruso R, Ayyagari R. Phenotype and genotype of patients with autosomal recessive bestrophinopathy. <span><span class="ref-journal">Ophthalmic Genet. </span>2012;<span class="ref-vol">33</span>:123–9.</span> [<a href="/pubmed/21809908" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21809908</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.marano.2000.760">Marano F, Deutman AF, Leys A, Aandekerk AL. Hereditary retinal dystrophies and choroidal neovascularization. <span><span class="ref-journal">Graefes Arch Clin Exp Ophthalmol. </span>2000;<span class="ref-vol">238</span>:760–4.</span> [<a href="/pubmed/11045344" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11045344</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.marchant.2007.e70">Marchant D, Yu K, Bigot K, Roche O, Germain A, Bonneau D, Drouin-Garraud V, Schorderet DF, Munier F, Schmidt D, Le Neindre P, Marsac C, Menasche M, Dufier JL, Fischmeister R, Hartzell C, Abitbol M. New VMD2 gene mutations identified in patients affected by Best vitelliform macular dystrophy. <span><span class="ref-journal">J Med Genet. </span>2007;<span class="ref-vol">44</span>:e70.</span> [<a href="/pmc/articles/PMC2598027/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2598027</span></a>] [<a href="/pubmed/17287362" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17287362</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.marmorstein.2000.12758">Marmorstein AD, Marmorstein LY, Rayborn M, Wang X, Hollyfield JG, Petrukhin K. Bestrophin, the product of the Best vitelliform macular dystrophy gene (VMD2), localizes to the basolateral plasma membrane of the retinal pigment epithelium. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2000;<span class="ref-vol">97</span>:12758–63.</span> [<a href="/pmc/articles/PMC18837/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC18837</span></a>] [<a href="/pubmed/11050159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11050159</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.marmorstein.2002.30591">Marmorstein LY, McLaughlin PJ, Stanton JB, Yan L, Crabb JW, Marmorstein AD. Bestrophin interacts physically and functionally with protein phosphatase 2A. <span><span class="ref-journal">J Biol Chem. </span>2002;<span class="ref-vol">277</span>:30591–7.</span> [<a href="/pubmed/12058047" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12058047</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.marquardt.1998.1517">Marquardt A, St&#x000f6;hr H, Passmore LA, Kr&#x000e4;mer F, Rivera A, Weber BH. Mutations in a novel gene, VMD2, encoding a protein of unknown properties cause juvenile-onset vitelliform macular dystrophy (Best's disease). <span><span class="ref-journal">Hum Mol Genet. </span>1998;<span class="ref-vol">7</span>:1517–25.</span> [<a href="/pubmed/9700209" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9700209</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.miller.1976.252">Miller SA, Bresnick GH, Chandra SR. Choroidal neovascular membrane in Best's vitelliform macular dystrophy. <span><span class="ref-journal">Am J Ophthalmol. </span>1976;<span class="ref-vol">82</span>:252–5.</span> [<a href="/pubmed/949077" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 949077</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.mohler.1981.688">Mohler CW, Fine SL. Long-term evaluation of patients with Best's vitelliform dystrophy. <span><span class="ref-journal">Ophthalmology. </span>1981;<span class="ref-vol">88</span>:688–92.</span> [<a href="/pubmed/7267039" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7267039</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.mullins.2005.1588">Mullins RF, Oh KT, Heffron E, Hageman GS, Stone EM. Late development of vitelliform lesions and flecks in a patient with best disease: clinicopathologic correlation. <span><span class="ref-journal">Arch Ophthalmol. </span>2005;<span class="ref-vol">123</span>:1588–94.</span> [<a href="/pubmed/16286623" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16286623</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.palmowski.2003.145">Palmowski AM, Allgayer R, Heinemann-Vernaleken B, Scherer V, Ruprecht KW. Detection of retinal dysfunction in vitelliform macular dystrophy using the multifocal ERG (MF-ERG). <span><span class="ref-journal">Doc Ophthalmol. </span>2003;<span class="ref-vol">106</span>:145–52.</span> [<a href="/pubmed/12678279" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12678279</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.palomba.2000.260">Palomba G, Rozzo C, Angius A, Pierrottet CO, Orzalesi N, Pirastu M. A novel spontaneous missense mutation in VMD2 gene is a cause of a best macular dystrophy sporadic case. <span><span class="ref-journal">Am J Ophthalmol. </span>2000;<span class="ref-vol">129</span>:260–2.</span> [<a href="/pubmed/10682987" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10682987</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.patel.2008.768">Patel N, Adewoyin T, Chong NV. Age-related macular degeneration: a perspective on genetic studies. <span><span class="ref-journal">Eye. </span>2008;<span class="ref-vol">22</span>:768–76.</span> [<a href="/pubmed/17491602" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17491602</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.petrukhin.1998.241">Petrukhin K, Koisti MJ, Bakall B, Li W, Xie G, Marknell T, Sandgren O, Forsman K, Holmgren G, Andreasson S, Vujic M, Bergen AA, McGarty-Dugan V, Figueroa D, Austin CP, Metzker ML, Caskey CT, Wadelius C. Identification of the gene responsible for Best macular dystrophy. <span><span class="ref-journal">Nat Genet. </span>1998;<span class="ref-vol">19</span>:241–7.</span> [<a href="/pubmed/9662395" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9662395</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.pianta.2003.203">Pianta MJ, Aleman TS, Cideciyan AV, Sunness JS, Li Y, Campochiaro BA, Campochiaro PA, Zack DJ, Stone EM, Jacobson SG. In vivo micropathology of Best macular dystrophy with optical coherence tomography. <span><span class="ref-journal">Exp Eye Res. </span>2003;<span class="ref-vol">76</span>:203–11.</span> [<a href="/pubmed/12565808" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12565808</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.qu.2006.5411">Qu Z, Chien LT, Cui Y, Hartzell HC. The anion-selective pore of the bestrophins, a family of chloride channels associated with retinal degeneration. <span><span class="ref-journal">J Neurosci. </span>2006;<span class="ref-vol">26</span>:5411–9.</span> [<a href="/pmc/articles/PMC6675304/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6675304</span></a>] [<a href="/pubmed/16707793" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16707793</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.querques.2008.501">Querques G, Regenbogen M, Quijano C, Delphin N, Soubrane G, Souied EH. High-definition optical coherence tomography features in vitelliform macular dystrophy. <span><span class="ref-journal">Am J Ophthalmol. </span>2008;<span class="ref-vol">146</span>:501–7.</span> [<a href="/pubmed/18619572" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18619572</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.querques.2009.2960">Querques G, Zerbib J, Santacroce R, Margaglione M, Delphin N, Rozet JM, Kaplan J, Martinelli D, Delle Noci N, Soubrane G, Souied EH. Functional and clinical data of Best vitelliform macular dystrophy patients with mutations in the BEST1 gene. <span><span class="ref-journal">Mol Vis. </span>2009;<span class="ref-vol">15</span>:2960–72.</span> [<a href="/pmc/articles/PMC2802291/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2802291</span></a>] [<a href="/pubmed/20057903" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20057903</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.renner.2004.929">Renner AB, Tillack H, Kraus H, Kohl S, Wissinger B, Mohr N, Weber BH, Kellner U, Foerster MH. Morphology and functional characteristics in adult vitelliform macular dystrophy. <span><span class="ref-journal">Retina. </span>2004;<span class="ref-vol">24</span>:929–39.</span> [<a href="/pubmed/15579992" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15579992</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.rudolph.2003.154">Rudolph G, Kalpadakis P. Topographic mapping of retinal function with the SLO-mfERG under simultaneous control of fixation in Best's disease. <span><span class="ref-journal">Ophthalmologica. </span>2003;<span class="ref-vol">217</span>:154–9.</span> [<a href="/pubmed/12592056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12592056</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.schatz.2006.51">Schatz P, Klar J, Andr&#x000e9;asson S, Ponjavic V, Dahl N. Variant phenotype of Best vitelliform macular dystrophy associated with compound heterozygous mutations in VMD2. <span><span class="ref-journal">Ophthalmic Genet. </span>2006;<span class="ref-vol">27</span>:51–6.</span> [<a href="/pubmed/16754206" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16754206</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.scholl.2002.1053">Scholl HP, Schuster AM, Vonthein R, Zrenner E. Mapping of retinal function in Best macular dystrophy using multifocal electroretinography. <span><span class="ref-journal">Vision Res. </span>2002;<span class="ref-vol">42</span>:1053–61.</span> [<a href="/pubmed/11934455" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11934455</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.seddon.2001.2060">Seddon JM, Afshari MA, Sharma S, Bernstein PS, Chong S, Hutchinson A, Petrukhin K, Allikmets R. Assessment of mutations in the Best macular dystrophy (VMD2) gene in patients with adult-onset foveomacular vitelliform dystrophy, age-related maculopathy, and bull's-eye maculopathy. <span><span class="ref-journal">Ophthalmology. </span>2001;<span class="ref-vol">108</span>:2060–7.</span> [<a href="/pubmed/11713080" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11713080</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.sun.2002.4008">Sun H, Tsunenari T, Yau KW, Nathans J. The vitelliform macular dystrophy protein defines a new family of chloride channels. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2002;<span class="ref-vol">99</span>:4008–13.</span> [<a href="/pmc/articles/PMC122639/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC122639</span></a>] [<a href="/pubmed/11904445" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11904445</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.testa.2008.1467">Testa F, Rossi S, Passerini I, Sodi A, Di Iorio V, Interlandi E, Della Corte M, Menchini U, Rinaldi E, Torricelli F, Simonelli F. A normal electro-oculography in a family affected by Best disease with a novel spontaneous mutation of the BEST1 gene. <span><span class="ref-journal">Br J Ophthalmol. </span>2008;<span class="ref-vol">92</span>:1467–70.</span> [<a href="/pubmed/18703557" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18703557</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.white.2000.301">White K, Marquardt A, Weber BH. VMD2 mutations in vitelliform macular dystrophy (Best disease) and other maculopathies. <span><span class="ref-journal">Hum Mutat. </span>2000;<span class="ref-vol">15</span>:301–8.</span> [<a href="/pubmed/10737974" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10737974</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.yardley.2004.3683">Yardley J, Leroy BP, Hart-Holden N, Lafaut BA, Loeys B, Messiaen LM, Perveen R, Reddy MA, Bhattacharya SS, Traboulsi E, Baralle D, De Laey JJ, Puech B, Kestelyn P, Moore AT, Manson FD, Black GC. Mutations of VMD2 splicing regulators cause nanophthalmos and autosomal dominant vitreoretinochoroidopathy (ADVIRC). <span><span class="ref-journal">Invest Ophthalmol Vis Sci. </span>2004;<span class="ref-vol">45</span>:3683–9.</span> [<a href="/pubmed/15452077" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15452077</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.yu.2006.4956">Yu K, Cui Y, Hartzell HC. The bestrophin mutation A243V, linked to adult-onset vitelliform macular dystrophy, impairs its chloride channel function. <span><span class="ref-journal">Invest Ophthalmol Vis Sci. </span>2006;<span class="ref-vol">47</span>:4956–61.</span> [<a href="/pubmed/17065513" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17065513</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.yu.2007.4694">Yu K, Qu Z, Cui Y, Hartzell HC. Chloride channel activity of bestrophin mutants associated with mild or late-onset macular degeneration. <span><span class="ref-journal">Invest Ophthalmol Vis Sci. </span>2007;<span class="ref-vol">48</span>:4694–705.</span> [<a href="/pubmed/17898294" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17898294</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.yu.2008.5660">Yu K, Xiao Q, Cui G, Lee A, Hartzell HC. The Best disease-linked Cl- channel hBest1 regulates Ca V 1 (L-type) Ca2+ channels via src-homology-binding domains. <span><span class="ref-journal">J Neurosci. </span>2008;<span class="ref-vol">28</span>:5660–70.</span> [<a href="/pmc/articles/PMC2587081/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2587081</span></a>] [<a href="/pubmed/18509027" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18509027</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.zhao.2012.866">Zhao L, Grob S, Corey R, Krupa M, Luo J, Du H, Lee C, Hughes G, Lee J, Quach J, Zhu J, Shaw PX, Kozak I, Zhang K. A novel compound heterozygous mutation in the BEST1 gene causes autosomal recessive Best vitelliform macular dystrophy. <span><span class="ref-journal">Eye (Lond). </span>2012;<span class="ref-vol">26</span>:866–71.</span> [<a href="/pmc/articles/PMC3376281/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3376281</span></a>] [<a href="/pubmed/22422030" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22422030</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bvd.REF.zhuk.2006.811">Zhuk SA, Edwards AO. Peripherin/RDS and VMD2 mutations in macular dystrophies with adult-onset vitelliform lesion. <span><span class="ref-journal">Mol Vis. </span>2006;<span class="ref-vol">12</span>:811–5.</span> [<a href="/pubmed/16885924" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16885924</span></a>]</div></li></ul></div></div><div id="bvd.Chapter_Notes"><h2 id="_bvd_Chapter_Notes_">Chapter Notes</h2><div id="bvd.Author_History"><h3>Author History</h3><p>Thomas Lee, MD (2003-present)<br />Ian M MacDonald, MD, CM (2003-present)<br />Dean Y Mah, MSc, MD; University of Alberta (2003-2009)</p></div><div id="bvd.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>12 December 2013 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>7 April 2009 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>8 December 2005 (me) Comprehensive update posted to live Web site</div></li><li class="half_rhythm"><div>27 October 2003 (imd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> clinically available</div></li><li class="half_rhythm"><div>30 September 2003 (me) Review posted to live Web site</div></li><li class="half_rhythm"><div>14 July 2003 (imd) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1167</span><span class="label">PMID: <a href="/pubmed/20301346" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301346</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/bscl/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/bpan/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1167&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1167/?report=reader">PubReader</a></li><li><a href="/books/NBK1167/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1167" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1167" style="display:none" title="Cite this Page"><div class="bk_tt">MacDonald IM, Lee T. Best Vitelliform Macular Dystrophy. 2003 Sep 30 [Updated 2013 Dec 12]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1167/pdf/Bookshelf_NBK1167.pdf">PDF version of this page</a> (1.1M)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#bvd.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#bvd.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#bvd.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#bvd.Genetically_Related_Allelic_Disorder" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#bvd.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#bvd.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#bvd.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#bvd.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#bvd.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#bvd.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#bvd.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=7439[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">BEST1</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1481292" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1481292" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1481292" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1481292" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/21320969" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Autosomal recessive best vitelliform macular dystrophy: report of a family and management of early-onset neovascular complications.</a><span class="source">[Arch Ophthalmol. 2011]</span><div class="brieflinkpop offscreen_noflow">Autosomal recessive best vitelliform macular dystrophy: report of a family and management of early-onset neovascular complications.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Iannaccone A, Kerr NC, Kinnick TR, Calzada JI, Stone EM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Arch Ophthalmol. 2011 Feb; 129(2):211-7. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/21921978" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Autosomal dominant Best disease with an unusual electrooculographic light rise and risk of angle-closure glaucoma: a clinical and molecular genetic study.</a><span class="source">[Mol Vis. 2011]</span><div class="brieflinkpop offscreen_noflow">Autosomal dominant Best disease with an unusual electrooculographic light rise and risk of angle-closure glaucoma: a clinical and molecular genetic study.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Low S, Davidson AE, Holder GE, Hogg CR, Bhattacharya SS, Black GC, Foster PJ, Webster AR. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Mol Vis. 2011; 17:2272-82. Epub 2011 Aug 23.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28478472" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Adult onset Best's macular dystrophy (VMD2) with unilateral presentation.</a><span class="source">[Nepal J Ophthalmol. 2016]</span><div class="brieflinkpop offscreen_noflow">Adult onset Best's macular dystrophy (VMD2) with unilateral presentation.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Kamat P, Doshi P, Prabhudesai M, Prabhudesai S. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Nepal J Ophthalmol. 2016 Jul; 8(16):171-173. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/30725975" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Best Disease</a><span class="source">[StatPearls. 2019]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Best Disease<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Tripathy K, Salini B. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">StatPearls. 2019 Jan</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/30578502" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Best Vitelliform Macular Dystrophy.</a><span class="source">[Adv Exp Med Biol. 2018]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Best Vitelliform Macular Dystrophy.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Tsang SH, Sharma T. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Adv Exp Med Biol. 2018; 1085:157-158. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301346" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301346" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e040c7839a66ee2ba4a3081">Best Vitelliform Macular Dystrophy - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Best Vitelliform Macular Dystrophy - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:27:20-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal102&amp;ncbi_phid=CE8946B2E03F91910000000007BB031F&amp;ncbi_session=CE8946B2E040C781_1979SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1167%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1167&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1167/&amp;ncbi_pagename=Best Vitelliform Macular Dystrophy - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8946B2E040C781_1979SID /projects/books/PBooks@5.22 portal102 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>